Livivos Inc.
San Diego, CA
- UEI
- HZ1JBLWN7DN8
- CAGE
- 8MYR2
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 4491 Yerba Santa Dr, San Diego, CA 92115, USA
- Website
- livivos.com
- Founded
- 2018
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Hemex Health Inc. | Portland, OR | 334510 Electromedical and Electrotherapeutic Apparatus Manufacturing |
| Cellia Science, Inc. | Fayetteville, AR | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Cortechs Al | San Diego, CA | — |
| Imggyd LLC | Middleton, WI | — |
| Sequitur Health Corp. | Scottsdale, AZ | 325413 In-Vitro Diagnostic Substance Manufacturing |
About the company
Livivos Inc. is a corporate, for-profit organization based in San Diego, California, registered in SAM.gov with active registration until January 31, 2026. The company appears to be focused on developing advanced medical diagnostic technologies, specifically innovative magnetic resonance (MR)-based devices for medical imaging and disease detection. Their primary product appears to be LIVERscope, a low-cost, point-of-care medical device designed to noninvasively assess liver health through quantitative biomarker measurements.
Livivos Inc. has received multiple federal grant awards primarily from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), focused on developing the LIVERscope device for diagnosing and monitoring metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD). The grants, totaling approximately $309,974, support the development of a novel medical diagnostic technology that can estimate proton-density fat fraction (PDFF) and potentially T1 relaxation time as biomarkers of liver health. The company's strategic approach involves conducting phase-based research to validate the device's accuracy, with the ultimate goal of obtaining FDA 510(k) clearance and bringing the LIVERscope to market. The device is designed to be versatile, capable of being used in standard clinical settings or mobile diagnostic environments, with the potential to transform medical care by enabling earlier diagnosis and treatment monitoring for liver disease.
Quick answers
Is Livivos Inc. registered in SAM.gov?
Yes. Livivos Inc.'s SAM.gov registration is active through August 31, 2027.
What is Livivos Inc.'s most recent federal award?
Livivos Inc.'s most recent federal grant award is Point-of care MR device to estimate T1 relaxation time as a biomarker of liver disease (resubmission) (R43EB034626), from National Institute of Biomedical Imaging and Bioenginering (NIH), on September 20, 2023.
On GovTribe
See Livivos Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors